Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancerJARY, Marine; GHIRINGHELLI, Francois; ARNOULD, Laurent et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 1, pp 141-150, issn 0344-5704, 10 p.Article

A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancerHALMOS, Balazs; YUXIA JIA; BOKAR, Joseph A et al.Investigational new drugs. 2013, Vol 31, Num 5, pp 1244-1250, issn 0167-6997, 7 p.Article

Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancerKU, Geoffrey Y; ILSON, David H; SCHWARTZ, Lawrence H et al.Cancer chemotherapy and pharmacology. 2008, Vol 62, Num 5, pp 875-880, issn 0344-5704, 6 p.Article

Reduced folate carrier gene G80A polymorphism is associated with an increased risk of gastroesophageal cancers in a chinese populationLINA WANG; WENSEN CHEN; JIANMIN WANG et al.European journal of cancer (1990). 2006, Vol 42, Num 18, pp 3206-3211, issn 0959-8049, 6 p.Article

A Third-Generation Herpesvirus Is Effective Against Gastroesophageal CancerWONG, Joyce; KELLY, Kaitlyn; MITTRA, Arjun et al.The Journal of surgical research (Print). 2010, Vol 163, Num 2, pp 214-220, issn 0022-4804, 7 p.Article

Gastric cancer in the era of molecularly targeted agents: current drug development strategiesARKENAU, Hendrik-Tobias.Journal of cancer research and clinical oncology. 2009, Vol 135, Num 7, pp 855-866, issn 0171-5216, 12 p.Article

Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancersKRZYSTEK-KORPACKA, Malgorzata; MATUSIEWICZ, Malgorzata; DIAKOWSKA, Dorota et al.Clinical chemistry and laboratory medicine. 2008, Vol 46, Num 3, pp 359-364, issn 1434-6621, 6 p.Article

Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuffZENDEHDEL, Kazem; NYREN, Olof; JUHUA LUO et al.International journal of cancer. 2008, Vol 122, Num 5, pp 1095-1099, issn 0020-7136, 5 p.Article

Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancersAJANI, Jaffer.Cancer. 2006, Vol 107, Num 2, pp 221-231, issn 0008-543X, 11 p.Article

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer ― Differential treatment strategies for subtypes of early gastroesophageal cancerLUTZ, Manfred P; ZALCBERG, John R; JANSEN, Edwin P. M et al.European journal of cancer (1990). 2012, Vol 48, Num 16, pp 2941-2953, issn 0959-8049, 13 p.Article

The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancerAL-BATRAN, S.-E; PAULIGK, C; ALTMANNSBERGER, H.-M et al.Annals of oncology. 2012, Vol 23, Num 7, pp 1699-1705, issn 0923-7534, 7 p.Article

Body Mass Index and Socioeconomic Status Measured in Adolescence, Country of Origin, and the Incidence of Gastroesophageal Adenocarcinoma in a Cohort of 1 Million MenLEVI, Zohar; KARK, Jeremy D; SHAMISS, Ari et al.Cancer. 2013, Vol 119, Num 23, pp 4086-4093, issn 0008-543X, 8 p.Article

Optimizing Docetaxel Chemotherapy in Patients With Cancer of the Gastric and Gastroesophageal Junction : Evolution of the Docetaxel, Cisplatin, and 5-fluorouracil RegimenAJANI, Jaffer A.Cancer. 2008, Vol 113, Num 5, pp 945-955, issn 0008-543X, 11 p.Article

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysisJANJIGIAN, Y. Y; WERNER, D; SHAH, M. A et al.Annals of oncology. 2012, Vol 23, Num 10, pp 2656-2662, issn 0923-7534, 7 p.Article